Is Pulse Biosciences (PLSE) Fully Valued After Its Recent Surge?
Pulse Biosciences (PLSE) has drawn attention after recent share performance, with the stock closing at $48.79 and showing sizeable moves over the past month and past 3 months. Investors are weighing what this means for future expectations.
Recent trading has cooled slightly, with the share price down 8.36% over the last session and 6.34% over the past week. Even so, Pulse Biosciences still shows strong momentum given its 30 day share price return of 15.04% and year to date gain of 264.38%, alongside a very large 3 year total shareholder return that signals how sharply market expectations around the company have shifted.
Scan beyond Pulse Biosciences to see how its recent price movement compares with a curated group of high momentum and quality plays in our 17 high quality undiscovered gems.
Bulls see Pulse Biosciences as a high growth bioelectric medicine platform whose recent surge simply reflects a rerating. Bears point to losses and the gap to analyst targets. Which story does the current valuation support?
Most Popular Narrative: 8% Overvalued
The most followed valuation view on Pulse Biosciences pegs fair value at $45.25, which sits below the recent $48.79 close and frames the current rerating as ahead of that narrative.
Early commercial traction of the nPulse Vybrance system in benign thyroid nodule ablation, supported by growing procedure volumes and positive physician feedback, positions the company to convert existing thyroidectomy volume and unlock a large base of watchful waiting patients, which should accelerate revenue growth and increase recurring disposable sales.
Want to see what kind of revenue ramp, margin shift, and future earnings multiple that fair value bakes in? The narrative spells out those assumptions with a detailed growth path and a specific profit profile that sits behind the $45.25 figure.
Result: Fair Value of $45.25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the story around Pulse Biosciences can change quickly if pivotal nsPFA trials disappoint, or if reimbursement and guideline support prove slower than analysts currently assume.
Find out about the key risks to this Pulse Biosciences narrative.
Next Steps
Opinions are mixed on whether Pulse Biosciences now reflects too much optimism in its price or still underestimates the opportunity, given both the flagged risk factors and potential upside drivers. It makes sense to stress test the full picture yourself with the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Pulse Biosciences?
Do not stop with Pulse Biosciences when the wider market is full of other opportunities that could suit your return goals and risk comfort.
- Target dependable cash generators by reviewing the 6 dividend fortresses that could complement a growth heavy portfolio.
- Hunt for potential mispricings with the 49 high quality undervalued stocks that filters for quality fundamentals first, not hype.
- Strengthen your downside protection by scanning the 82 resilient stocks with low risk scores so you are not caught off guard when market volatility picks up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com